Sign In
Buy NVS
$148.93
+1.85 (+1.26%)
At Close: Jun 22, 2026
Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases
01:15am, Monday, 01'st Jun 2026
Basel, June 1, 2026 – Novartis will present new data from 31 abstracts across its industry-leading immunology portfolio at the European Alliance of Associations for Rheumatology (EULAR) Congress on
Experimental Novartis radiopharma drug shows promise in early study
07:16am, Sunday, 31'st May 2026
Novartis said on Sunday that early data from its experimental actinium-based drug showed signs of anti-tumour activity against prostate cancer, including in patients previously treated with its old
Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer
01:15am, Sunday, 31'st May 2026
Basel, May 31, 2026 – Novartis today announced results showing consistent radiographic progression-free survival (rPFS) improvement across key subgroups with Pluvicto™ (lutetium Lu 177 vipivotide
New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength
01:15am, Tuesday, 26'th May 2026
Basel, May 26, 2026 – Novartis will present data from 15 abstracts from its kidney portfolio at this year's European Renal Association (ERA) Congress in Glasgow, June 3-6. The presentations reinforc
Basel, May 21, 2026 – Novartis will present data from more than 65 company or investigator sponsored abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the Europea
3 International ETFs for Investors Looking Beyond U.S. Stocks
09:00pm, Monday, 18'th May 2026
These three international ETFs offer diversification and surprisingly strong dividends -- with the same low expense ratio of 0.07%.
Cancer Stocks That Are Advancing the Future of Oncology Care
01:01pm, Monday, 18'th May 2026
Oncology innovation is accelerating as AI, immunotherapy and targeted drugs drive growth for cancer-focused biotech and pharma stocks.
New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer
03:30pm, Sunday, 17'th May 2026
Basel, May 17, 2026 – Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto® (lutetium (177Lu) vipivotide tetraxetan) co
Isomorphic Labs' $2.1 Billion Fundraise Is The Biggest Bet Yet On AI Drug Discovery
06:15pm, Wednesday, 13'th May 2026
On Tuesday, Isomorphic Labs, the Alphabet-founded firm that uses AI to accelerate drug development, said that it had raised $2.1 billion from investors led by Thrive Capital. That's a boatload of cash
Implied Volatility Surging for Novartis Stock Options
10:05am, Wednesday, 13'th May 2026
Investors need to pay close attention to NVS stock based on the movements in the options market lately.
Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities
09:00am, Thursday, 07'th May 2026
Basel, May 7, 2026 – Novartis, a leading global innovative medicines company, today broke ground on its new 46,000 sq. ft radioligand therapy (RLT) manufacturing site in Denton, Texas, the latest mi
Novartis to cut 220 jobs as it closes German site
08:16am, Tuesday, 05'th May 2026
Swiss drugmaker Novartis said on Tuesday that it is set to cut around 220 jobs in Germany as part of the planned closure of a production site by the end of 2028.
Novartis AG (NVS) Stock Up 3.4% but GF Value Says Overvalued -- GF Score: 83/100
05:06pm, Thursday, 30'th Apr 2026
On April 30, 2026, Novartis AG (NVS) shares rose 3.4% today, bringing the current price to $147.85. This price is within a 52-week range of $104.93 to $170.46,
Concurrent Investment Advisors LLC Grows Position in Novartis AG $NVS
02:10pm, Wednesday, 29'th Apr 2026
Concurrent Investment Advisors LLC raised its holdings in shares of Novartis AG (NYSE: NVS) by 36.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchang
UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies
05:32am, Wednesday, 29'th Apr 2026
Britain's largest drugmakers saw 2026 get off on a positive note, with AstraZeneca and GSK both reporting core earnings ahead of expectations on Wednesday The CEOs of a number of European pharma giant
